CLEVELAND, July 21, 2014 /PRNewswire/ –
DATATRAK International, Inc. (OTCQX: DTRK), the
leader in developing cloud-based, unified
eClinical® technologies and delivering
related services for the clinical trials industry, today announced
Pegus Research has entered a multi-year Enterprise Agreement for
DATATRAK solutions and services.
"We are proud to count Pegus among our DATATRAK
partners," said Laurence P. Birch,
Chairman and CEO, DATATRAK. "They have seen, first
hand, the safe acceleration of trials with the DATATRAK
ONE® Unified Experience™
solutions," said Birch. "The move from trial-by-trial use to
an Enterprise Agreement provides additional advantages, including
removing the constraints of repetitive contracting, establishing
long-term consistent pricing, enhancing access to
DATATRAK technology and services, and creating a
central library for standardized eCRF usage across all of their
sponsor trials," concluded Birch.
The Unified Experience™ triggers advantages
to each solution of the Unified Platform, with increased benefits
realized from increased product usage.
UX
CTMS™
|
Plan and Manage Your
Trial
|
UX Trial
Design™
|
Design-to-Deployment
in One Tool
|
UX EDC &
Medical
Coding™
|
Capture and Deliver
Your Data
|
UX Randomization
& Trial Supply
|
|
Management™(UX
RTMS™)
|
Randomize Patients
& Automate Supply
|
UX Patient Data
Capture™
|
Collect Patient
Driven Data
|
UX
Safety™
|
Manage Individual
Case Safety Reports
|
UX
Training™
|
Train Users and Track
Certificates
|
"PEGUS Research is pleased for the opportunity to partner with
DATATRAK to deliver the most efficient and flexible
EDC architecture possible to our pharmaceutical clients and sites.
With enhanced features like question visibility logic, the
DATATRAK ONE® Unified Platform has proven to be
the most robust and advanced solution for meeting the unique design
requirements of all the EDC studies PEGUS conducts," said
Clark Richardson, President of PEGUS
Research.
The DATATRAK ONE®
Unified Experience™ removes clinical research
complexities, accelerating the ultimate outcome of every trial. The
strength of DATATRAK eClinical solutions is the
intrinsic connection to the DATATRAK
ONE® Unified Platform, with all
products powered by a single data source providing exceptional
system reliability, eliminating the need for integration and
minimizing downtime, enabling agile mid-study changes, delivered
through an easy-to-use interface. Powered by the Cloud, the
DATATRAK ONE® Unified Experience™
solutions result in better site compliance, better data, and
ultimately a safer trial
Join DATATRAK Thought Leaders:
- Twitter
- LinkedIn
- SlideShare
- The DATATRAK Blog
Tweet: .@PEGUSresearch & DATATRAK Enterprise Agreement
Confirmed Upgrading trial by trial partnership #eClinical
http://bit.ly/1mZWz9n
About
DATATRAK International,
Inc.
DATATRAK International is a worldwide
technology and services company delivering unified
eClinical® solutions and related services for the
clinical trials industry. DATATRAK built its
multi-component, comprehensive solution on a single, unified
platform and expanded this concept to include services delivery via
the DATATRAK Clinical and Consulting Services group.
The Company delivers a complete portfolio of software products
designed to accelerate the reporting of clinical research data from
sites to sponsors and ultimately regulatory authorities, faster and
more efficiently than loosely integrated technologies. The
DATATRAK ONE® software solution, deployed
worldwide through an ASP or Enterprise Transfer offering, supports
Preclinical and Phase I - Phase IV drug and device studies in
multiple languages throughout the world. DATATRAK is
located in Cleveland, Ohio;
Bryan, Texas; Cary (RTP),
North Carolina, and the UK.
For more information, visit http://www.datatrak.com.
Except for the historical information contained in this press
release, the statements made in this release are forward-looking
statements. These forward-looking statements
are made based on management's expectations, assumptions, estimates
and current beliefs concerning the operations, future results and
prospects of the Company and are subject to uncertainties and
factors which are difficult to predict and, in many instances, are
beyond the control of the Company, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. For a list of certain factors that may
cause actual results to differ materially from those contemplated
in these forward looking statements, please see the Company's
report filed with the OTCQX Market on May
14, 2014 announcing its results for the first quarter period
ending March 31, 2014. The Company
undertakes no obligation to update publicly or revise any
forward-looking statement whether as a result of new information,
future events or otherwise.
SOURCE DATATRAK International, Inc.